Document Detail

Charged particles in radiotherapy: a 5-year update of a systematic review.
MedLine Citation:
PMID:  22326572     Owner:  NLM     Status:  MEDLINE    
Although proton therapy has been used for many decades because of their superior dose distribution over photons and reduced integral dose, their clinical implementation is still controversial. We updated a systematic review of charged particle therapy. Although still no randomised trials were identified, the field is moving quickly and we therefore also formulated ways to move forward. In our view, the aim should be to build enough proton therapy facilities with interest in research to further improve the treatment and to run the needed clinical trials.
Dirk De Ruysscher; M Mark Lodge; Bleddyn Jones; Michael Brada; Alastair Munro; Thomas Jefferson; Madelon Pijls-Johannesma
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-02-10
Journal Detail:
Title:  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology     Volume:  103     ISSN:  1879-0887     ISO Abbreviation:  Radiother Oncol     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-16     Completed Date:  2012-08-10     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  8407192     Medline TA:  Radiother Oncol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  5-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Neoplasms / radiotherapy*
Protons / therapeutic use*
X-Ray Therapy
Grant Support
10588//Cancer Research UK
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Robust stabilization and H(?) controllers design for stochastic genetic regulatory networks with tim...
Next Document:  Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate c...